Phase 1b Study of Teclistamab in Relapsed/Refractory Plasmablastic Lymphoma
Latest Information Update: 03 Mar 2026
At a glance
- Drugs Teclistamab (Primary)
- Indications Plasmablastic lymphoma
- Focus Adverse reactions
Most Recent Events
- 25 Feb 2026 Planned initiation date changed from 26 Feb 2026 to 29 May 2026.
- 21 Jan 2026 New trial record